Last reviewed · How we verify
Prevention of Bronchospasm with Chronic Bronchitis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Arcapta Neohaler | INDACATEROL | Novartis | beta2-Adrenergic Agonist | Beta-2 adrenergic receptor | 2011-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Novartis · 1 drug in Prevention of Bronchospasm with Chronic Bronchitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of Bronchospasm with Chronic Bronchitis:
- Prevention of Bronchospasm with Chronic Bronchitis treatment updates — RSS
- Prevention of Bronchospasm with Chronic Bronchitis treatment updates — Atom
- Prevention of Bronchospasm with Chronic Bronchitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of Bronchospasm with Chronic Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-bronchospasm-with-chronic-bronchitis. Accessed 2026-06-10.
Related
- Prevention of Bronchospasm with Chronic Bronchitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing